Global Net Lease (NYSE:GNL) Stock, Quote.Headers.trade-ideas

Global Net Lease

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail ; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

inflation ai2

Equities

Large Cap

Mid Cap

Sector ETFs

Small Cap

Econ #s

Federal Reserve

ETFs

EGBN

EXPI

FFIC

HOUS

LBAI

NYCB

OCFC

OPEN

PKST

RMAX

SFBS

XLRE

Select Sector SPDR-Consumer Discretionary

Inflation unexpectedly surges, shattering hopes for Fed rate cuts &amp; sending stocks down. Core inflation also exceeded expectations. No sector escapes losses, with real estate hit hardest.

Real Estate, Regional Bank Stocks Tank, Energy Cushions The Blow: March Inflation Rates Shake Up Sectors

Man's,Right,Hand,Is,Preparing,To,Pick,A,Rolled,Up

REIT

Real Estate

ACRE

GIPR

Watch Out - These 5 REITs Could Be Yield Traps

Reit,Real,Estate,Investment,Trust,Symbol.,Concept,Words,Reit,Real

UNIT

3 REITs Yielding Over 10% to Buy in 2024

Global Net Lease Inc

GENESIS LAND DEV CORP by Genesis Land Development Corp.

Genesis Land Development Corp

Genelink Inc

Greenlane Holdings, Inc. - Class A Common Stock

Greenlane Holdings Inc

Genelux Corp

Global Net Lease, Inc. 7.25% Series A Cumulative Redeemable Preferred Stock, $0.01 par value per share

Global Net Lease, Inc. 6.875% Series B Cumulative Redeemable Perpetual Preferred Stock

Global Net Lease, Inc. 7.50% Series D Cumulative Redeemable Perpetual Preferred Stock

Global Net Lease, Inc. 7.375% Series E Cumulative Redeemable Perpetual Preferred Stock

-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 --

News

QTTB

Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024

Three U.S.-based economists have been awarded the prestigious Nobel Prize in Economic Sciences for their significant contributions to understanding global wealth inequality. 
As per the official press release, U.S.-based economists Daron Acemoglu, Simon Johnson, and James Robinson were awarded the Nobel Prize in Economic Sciences on Monday. The trio was recognized for their groundbreaking research on wealth inequality between nations.
The Nobel Committee highlighted their work on how societies with inadequate legal frameworks and exploitative institutions fail to achieve economic growth. Acemoglu and Johnson are professors at the Massachusetts Institute of Technology, while Robinson is the director of the University of Chicago&#8217;s Pearson Institute.
See Also: <a href="https://www.benzinga.com/news/24/10/41303300/mary-trump-because-donald-is-a-world-class-hypocrite-it-turns-out-his-interviews-have-been-edited?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mary Trump: &#8216;Because Donald Is A World-Class Hypocrite, It Turns Out His Interviews Have Been Edited&#8217;</a>
Their influential 2012 book, &#8220;Why Nations Fail: The Origins of Power, Prosperity, and Poverty,&#8221; delves into the roots of inequality and the factors that enable some countries to thrive. Jakob Svensson from Stockholm University praised their empirical and theoretical contributions to understanding global inequality.
The winners will share the prize money of 11 million Swedish kronor ($1.058 million), awarded by the Swedish central bank. This award, formally known as the &#8220;Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel,&#8221; was first introduced in 1968.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41303750/elon-musks-new-cybercab-does-not-have-stainless-steel-exterior-panels-like-cybertruck-despite-other?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s New Cybercab Does Not Have Stainless Steel Exterior Panels Like Cybertruck Despite Other Rese</a></li>
</ul>
Image via Wikimedia Commons
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Economics

General

US Economists Daron Acemoglu, Simon Johnson And James Robinson Win Nobel Prize For Groundbreaking Research On Global Wealth Inequality

Guggenheim analyst Seamus Fernandez initiates coverage on Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) with a Buy rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

TENX

Guggenheim Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $16

Morgan Stanley analyst Angel Castillo downgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Equal-Weight to Underweight and lowers the price target from $349 to $332.

Downgrades

Morgan Stanley Downgrades Caterpillar to Underweight, Lowers Price Target to $332

WIIM

BITF

CLSK

COIN

HIVE

MARA

RIOT

Shares of crypto-linked stocks and miners are trading higher amid a rise in Bitcoin.

<ul>
<li>The U.S. government&#39;s Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development &amp; funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV)</li>
<li>The funding advances opaganib&#39;s positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV</li>
<li>Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks</li>
<li>This year marks the 10th&nbsp;anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO)1</li>
<li>Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction. It is believed to be the first host-directed molecule to show activity in EBOV in vivo and represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. Additional U.S. government collaborations with opaganib are ongoing</li>
<li>Significant geopolitical and logistical challenges exist in managing outbreaks of disease and there is an urgent need for safe and effective, oral, small molecule therapeutics that can be stored and easily distributed and administered in an outbreak</li>
</ul>

RDHL

RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness

COHR

Coherent shares are trading higher after Needham maintained a Buy rating on the stock and raised its price target from $84 to $120. The company last week announced a new CFO.

enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

BLCO

Bausch + Lomb Says FDA Approved enVista Envy Full Range Of Vision Intraocular Lens

Bausch + Lomb Receives FDA Approval For The enVista Envy Full Vision Intraocular Lens Range

<a href="https://www.globenewswire.com/Tracker?data=thMGJcWW8AjTyfCdJD1xEBtP9-UfOazyoISk64JnA5BjVTgverx4tk3EokPzyivmSOugN4h9qO92NeHgMVH1owl-X3tJ-hIrPYB6qZ4UkYU=">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq:&nbsp;BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO&#xAE; (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO. &nbsp;
The study will be presented in a poster at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 national meeting, which is being held in Las Vegas from October 14-17, 2024.
"Our interrogation of claims data builds upon previously reported findings demonstrating that ORLADEYO not only has a favorable impact on the lives of patients with HAE – but the broader healthcare system, as well. Here, our analysis reveals that significant reductions in healthcare resource utilization are achieved across multiple outcomes – such as reductions in hospitalizations and medical visits, including those related to HAE attacks. Decreases in on-demand treatment were also observed. Taken together, our investigation provides promising real-world evidence which supports ORLADEYO's clinical and financial value as a prophylactic therapy for HAE," said Sandra Christiansen, MD, professor of medicine and director of translational research at the US HAEA Angioedema Center at the University of California, San Diego.
The poster Healthcare Resource Utilization among Patients Initiating Berotralstat for the Long Term Prophylaxis of Hereditary Angioedema in the United States (#D20) detailed findings from a retrospective pre-post study that featured analysis of administrative U.S. claims data of patients with HAE in the United States. The analysis focused on eligible patients enrolled in commercial and public health plans who initiated ORLADEYO between December 2020 and December 2022 who had a baseline of at least six months of continuous health plan enrollment prior to starting ORLADEYO&nbsp;(n=260).
<ul>
<li>Significant reductions in HRU were observed in the overall study population following initiation of ORLADEYO (p&lt;0.05), including in: 
<ul>
<li>All-cause hospitalizations (34 percent reduction) and outpatient or emergency room visits (14 percent reduction).</li>
<li>Angioedema-related hospitalizations (52 percent reduction) and outpatient or emergency room visits (44 percent reduction). &nbsp;</li>
</ul>
</li>
<li>Significant reductions in HAE attack-related HRU were also observed (p&lt;0.05), including in: 
<ul>
<li>HAE attack-related visits (51 percent reduction), driven by significant decreases in hospitalization (60 percent) and outpatient or emergency room visits (50 percent).</li>
<li>Reduction in HAE attack-related visits were observed when stratified by body location of the attack, including in the head and upper airways (48 percent reduction), gastrointestinal system (58 percent reduction) and unspecified locations (52 percent reduction).</li>
<li>Additionally, a decrease in use of on-demand therapies administered by a healthcare professional was observed (39 percent reduction) among patients who previously received on-demand treatment.</li>
</ul>
</li>
</ul>

BCRX

BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows

<ul>
<li>ServiceNow will double-down on commitment to UK with investments in expanded office space, significant employee growth and AI skills programmes</li>
<li>Plans to put AI to work for people in the UK with domain specific LLMs in UK data centres and AI reskilling programmes for British workers</li>
</ul>

ServiceNow Commits $1.5B To Expand UK Operations, Expanding Offices And Workforce, With Focus On AI Innovation

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's Phase 1 (POLAR) clinical trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. RP-3467 is Repare's fourth clinical program.
"RP-3467, our potential best-in-class Polθ ATPase inhibitor, has demonstrated highly compelling preclinical results, including complete and durable tumor regressions in combination with olaparib, the leading PARP inhibitor, with no additive toxicities. This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, a significant area of high unmet medical need," said Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. "In addition, Repare's previously reported data established the potential for RP-3467 to improve efficacy and limit toxicity in combination with radioligand therapy and chemotherapy-bearing antibody drug conjugates (ADCs), and we look forward to exploring those areas."
The POLAR clinical trial (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06560632&amp;esheet=54135120&amp;newsitemid=20241014582242&amp;lan=en-US&amp;anchor=NCT06560632&amp;index=1&amp;md5=f23673287757dd3835d063b90d4b5006">NCT06560632</a>) is a multicenter, open-label, dose-escalation Phase 1 clinical trial to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467 alone or in combination with the PARP inhibitor, olaparib, in adults with molecularly selected advanced solid tumors. The study is expected to enroll approximately 52 patients with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. The primary objectives of the study are to assess the safety and tolerability of RP-3467 alone and in combination with olaparib, and to define a preliminary recommended Phase 2 dose of RP-3467 in combination with olaparib.

RPTX

Repare Begins Clinical Trial Combining RP-3467 and PARP Inhibitor Olaparib to Fight Advanced Cancers

14 of 15 participants (93%) enrolled in both dose cohorts of the study (n=15) achieved a clinical response within the 6-week preliminary analysis period following administration.
In the 120mg dose cohort, 10 of 12 participants (83%) experienced a complete response (CR), and 1 participant experienced a partial response (PR). Briquilimab was well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported.
In alignment with the Company&#39;s clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study.&nbsp;
Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025.
Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during the week of January 6th, 2025, including the recently added 180mg Q8W dose cohort.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics Reports Preliminary Data From Ongoing SPOTLIGHT Phase 1b/2a Study Of Subcutaneous Briquilimab; Says 14 Of 15 Participants Enrolled Achieved Clinical Response

Unicycive Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that a poster presentation on oxylanthanum carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Unicycive will also deliver three additional poster presentations on OLC and UNI-494. The conference will take place October 24-27, 2024 in San Diego, CA. &nbsp;
Late Breaking Science Poster:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title: &nbsp;</td>
<td>Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia &nbsp;</td>
</tr>
<tr>
<td>Lead Author:</td>
<td>Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer &amp; Senior Vice President, Clinical Research&nbsp;&amp;&nbsp;Medical Affairs, U.S. Renal Care</td>
</tr>
<tr>
<td>Session Title:</td>
<td>Late-Breaking Science Posters [LB-PO]</td>
</tr>
<tr>
<td>Poster Board:</td>
<td>#TH-PO1188</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>Thursday, October 24, 2024 from 10:00 a.m. – 12:00 p.m. PT</td>
</tr>
</tbody>
</table>
</figure>
Three additional poster presentations:
&nbsp; &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title: &nbsp;</td>
<td>Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats &nbsp;</td>
</tr>
<tr>
<td>Lead Author:</td>
<td>Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive</td>
</tr>
<tr>
<td>Session Title:</td>
<td>AKI: Mechanisms</td>
</tr>
<tr>
<td>Poster Board:</td>
<td>#FR-PO155</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>Friday, October 25, 2024 from 10:00 a.m. – 12:00 p.m. PT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title: &nbsp;</td>
<td>Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat &nbsp;</td>
</tr>
<tr>
<td>Lead Author:</td>
<td>Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive</td>
</tr>
<tr>
<td>Session Title:</td>
<td>CKD-MBD: Basic and Translational</td>
</tr>
<tr>
<td>Poster Board:</td>
<td>#SA-PO243</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title: &nbsp;</td>
<td>UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics &nbsp;</td>
</tr>
<tr>
<td>Lead Author:</td>
<td>Guru Reddy, PH.D., Vice President of Preclinical R&amp;D, Unicycive</td>
</tr>
<tr>
<td>Session Title:</td>
<td>AKI: Clinical, Outcomes, and Trials - Management</td>
</tr>
<tr>
<td>Poster Board:</td>
<td>#SA-PO036</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT</td>
</tr>
</tbody>
</table>
</figure>
About Oxylanthanum Carbonate (OLC)
Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden for patients in terms of number and size of pills per dose that are swallowed instead of chewed. Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient compliance.1&nbsp;The global market opportunity for treating hyperphosphatemia is projected to be in excess of $2.5 billion in 2023, with the United States accounting for more than $1 billion of that total. Despite the availability of several FDA-cleared medications, 75 percent of U.S. dialysis patients fail to achieve the target phosphorus levels recommended by published medical guidelines.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. As part of the clinical development program, two clinical studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability. The second study was a randomized, open-label, two-way crossover bioequivalence study to establish pharmacodynamic bioequivalence between OLC and Fosrenol. Based on the results of the bioequivalence study, pharmacodynamic (PD) bioequivalence of OLC to Fosrenol was established. A pivotal clinical trial was also conducted in CKD patients on hemodialysis that achieved the study objective and established favorable tolerability of OLC at clinically effective doses.

UNCY

Unicycive to Present New Kidney Disease Research at ASN Kidney Week 2024

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) rose sharply in <a href="https://www.benzinga.com/quote/LBPH">today's pre-market trading</a>.
Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2.6 billion equity value.
Longboard Pharmaceuticals shares jumped 46.8% to $57.13 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Inventiva S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NYSE">IVA</a>) rose 86.2% to $3.52 in pre-market trading. The company raised up to €348 million to fund Phase 3 NATiV3 clinical trial for MASH, and named new chairman and director.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 92.2% to $0.7297 in pre-market trading. Tevogen Bio announced plans to share $1 billion+ revenue potential of its pipeline portfolio beginning week of Oct. 14.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares rose 72% to $4.1100 in pre-market trading after gaining 4% on Friday.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares surged 15% to $2.32 in pre-market trading after declining over 12% on Friday.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) gained 15% to $11.50 in pre-market trading.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) rose 14.3% to $5.02 in pre-market trading after declining 3% on Friday.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares jumped 12.4% to $1.27 in pre-market trading after gaining around 8% on Friday.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) climbed 9.3% to $1.99 in pre-market trading following a 5% gain on Friday.</li>
<li>Blend Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NASDAQ">BLND</a>) gained 7.7% to $3.92 in pre-market trading after gaining 3% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares dipped 76.8% to $0.3401 in pre-market trading as the company's board of directors approved the liquidation and wind-up of the company.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares fell 70.7% to $0.0765 in pre-market trading after gaining around 8% on Friday.</li>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) fell 44.1% to $0.0655 in today's pre-market trading. Vicinity Motor failed to renegotiate terms with creditors and concluded workout plan without restructuring.</li>
<li>Notable Labs, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) fell 25.8% to $0.2896 in pre-market trading.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares declined 22.4% to $5.54 in pre-market trading after surging 238% on Friday.</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares declined 18.8% to $0.39 in pre-market trading after gaining 17% on Friday. SIMPPLE, last week, announced new contracts and partnerships in Australia and New Zealand.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 17.1% to $0.8125 in pre-market trading after surging 63% on Friday.</li>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares fell 15% to $0.8501 after declining 5% on Friday.</li>
<li>BAIYU Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYU#NASDAQ">BYU</a>) declined 13.3% to $0.26 in pre-market trading after declining 35% on Friday.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) fell 6.6% to $1.85 in pre-market trading after jumping around 28% on Friday.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308141/this-analyst-with-85-accuracy-rate-sees-around-20-upside-in-amd-here-are-5-stock-picks-for-last-week"> This Analyst With 85% Accuracy Rate Sees Around 20% Upside In AMD &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARBK

BLND

CERS

DXYZ

LBPH

MTEM

NIVF

NTBL

PACB

RANI

RILY

SPPL

TVGN

XPON

ZPTA

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket

Bernstein analyst Brendan Luecke maintains GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Outperform and raises the price target from $201 to $225.

Bernstein Maintains Outperform on GE Aero, Raises Price Target to $225

The maximum amount payable under the all-cash performance-based earn-out is US&nbsp;$20 million, based on the combined business achieving revenue-based targets in each of the first two years post-acquisition. Any earn-out is expected to be paid in fiscal 2026 and fiscal 2027.

DSGX

Descartes Acquires New Jersey-Based Sellercloud For Up-front Consideration Of Approximately $110M Satisfied From Cash On Hand, Plus Additional Potential Performance-based Consideration

On Friday, Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) voluntarily recalled 12 types of ReadyMeals and deli items supplied by Fresh Creative Foods due to potential contamination <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41300393/albertsons-companies-voluntarily-recalls-12-readymeals-and-store-made-deli-items-containing-a-reca" rel="noreferrer noopener">with Listeria monocytogenes</a>.
The recalled ReadyMeals and deli items were sold at Albertsons, Safeway, Jewel-Osco, Vons, and stores across several states, including California, Texas, Illinois, and Washington.
The recall was prompted by Fresh Creative Foods&#8217; action after routine tests by the U.S. Department of Agriculture&#8217;s Food Safety and Inspection Service (FSIS) detected contamination in a ready-to-eat chicken ingredient from BrucePac in Durant, Oklahoma.
Listeria can cause serious infections in vulnerable groups, including the elderly, young children, and pregnant women, leading to symptoms like fever, nausea, and, in severe cases, miscarriages.
The company said those at risk should seek medical care if they experience flu-like symptoms after consuming contaminated food.
In September, Albertsons launched Bee Lightly, which features an innovative flat bottle made from 100% recycled PET— a<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41003147/albertsons-companies-launches-highly-rated-bee-lightly-wines-redefining-wine-packaging" rel="noreferrer noopener"> first in the U.S. wine industry</a>.
Investors can gain exposure to the stock via First Trust Cons. Staples AlphaDEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXG#NYSE">FXG</a>).
Price Action: ACI shares are up 0.05% at $18.38 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41272661/why-shrinking-price-differences-between-walmart-kroger-and-albertsons-matter-to-inv" target="_blank" rel="noreferrer noopener">Why Shrinking Price Differences Between Walmart, Kroger, And Albertsons Matter To Investors</a></li>
</ul>

Listeria Scare Prompts Albertsons To Recall Certain Ready-To-Eat Meals In Multiple States

U.S. stocks could get off to a mixed start on Monday after the <a href="https://www.benzinga.com/news/earnings/24/10/41298806/wall-street-marks-new-record-highs-on-strong-start-to-earnings-season-investors-downplay-inflation-">averages posted weekly gains for a fifth straight week. </a>The bond market is closed on account of Columbus Day, <a href="https://www.benzinga.com/news/24/10/41309748/columbus-day-is-stock-market-open-today">which is a federal holiday</a>, but the stock market will trade during usual hours. The majority opinion among strategists hints at a potential pause in stock rally over the next couple of weeks before resuming in the final two months of the year.
That said, earning news flow will pick up momentum in the coming days, potentially cushioning any downside. Cumulative earnings of S&amp;P 500 companies are set to rise for a fifth straight quarter, FactSet said. This, though, would mark a slowdown from the 11.2% growth reported for the second quarter.
On Monday, traders could focus on a couple of Fed speeches and a consumer inflation expectations survey as well as the bond yield even as they look ahead to some key earnings reports over the week.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.35%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.23%</td>
</tr>
<tr>
<td>Dow</td>
<td>-0.06%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.36%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) added 0.19% to $580.68 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) moved up 0.33% to $495.07, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Week:
Despite the consumer price inflation data throwing investors off guard, the market had enough momentum to keep the rally going in the week ended Oct. 11. A rise in bond yields following some recent strong data and the Hurricane Milton threat also exerted downward pressure on the market, but a benign producer price inflation report and a good start to big bank earnings provided the offsetting impact.
The Dow Jones Industrial Average and the S&amp;P 500 Index ended at fresh intraday and closing highs, while the Nasdaq Composite slowly progressed toward its previous closing high of 18,509.34 hit on July 16.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td> Week&#8217;s Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+1.13%</td>
<td>18,342.94</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+1.11%</td>
<td>5,815.03</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+1.21%</td>
<td>42,863.86</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+0.98%</td>
<td>2,188.42</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Yardeni Research reiterated its call for the S&amp;P 500 to hit 8,000 by 2030 under its &#8220;Roaring 2020s&#8221; scenario. The index will be supported on its way higher by earnings rather than rising valuation multiples, the firm said. The comments came in the aftermath of the second anniversary of the bull market that began on Oct. 12, 2022.
The period was marked by widespread fears of a recession due to monetary policy tightening, the firm said. &#8220;Those fears lingered through October 4 of this year, when a stronger-than-expected employment report once again confirmed that the young bull correctly discounted that inflation would fall while the economy remained resilient,&#8221; it said.
Since Oct. 12, 2022, all the major stock market indices are up at least 20%, with the S&amp;P 500 up 62.6%, Yardeni Research said. The S&amp;P 500&#8217;s performance is par for the course compared to the previous eight bull markets, it added.
As the momentum remains firmly to the upside, Fund Strat Head of Research Tom Lee said his firm has advised clients to remain cautious but at the same time buy the dips. In an interview with CNBC on Friday, the strategist <a href="https://x.com/CNBCClosingBell/status/1844818752359075865">said </a>investors want to see who ends up president. &#8220;We are in a period where the market is sitting on the sidelines,&#8221; he said.
At the same time, 2024 has been such a strong year, he said, adding that the last two weeks have proved that macro is taking a step back now, and liquidity and cash on the sidelines are becoming the dominant factor, Lee said. &#8220;There is a lot of firepower supporting stocks post election,&#8221; he said. 
The Fed is dovish, the economy looks healthy, and therefore the three- and six-month outlook is very strong for stocks, he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
This week&#8217;s economic calendar is dominated by Fed speeches, the September retail sales report and a few manufacturing and housing market data. The New York and Philadelphia Feds will release the results of their respective October manufacturing surveys and the Fed is due to announce its September industrial production data. Among the housing data due this week are the National Association of Home Builders housing market index for October and the Commerce Department&#8217;s housing starts report for September.
<ul>
<li>On Monday, Minneapolis Fed President Neel Kashkari will make public appearances at 9 am EDT and 5 pm EDT.</li>
<li>The New York Fed is due to release the results of its survey of consumer expectations for September at 11 a.m. EDT. In August, the one- and five-year ahead inflation expectations remained unchanged at 3% and 2.8%, respectively.</li>
<li>Federal Reserve Governor Christopher Waller&nbsp;is scheduled to speak at 3 p.m.</li>
</ul>
Stocks In Focus:
<ul>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) climbed 1.80% <a href="https://www.benzinga.com/premarket">in premarket trading</a> after Friday&#8217;s nearly 9% slump.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) climbed nearly 6% after Berkshire Hathaway, Inc. (NYSE; BRK-A) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) boosted its stake in the company.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell over 1.70% after the company announced the elimination of 10% of its workforce.</li>
<li>Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally past $64K sent crypto-linked stocks such as MicroStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) higher.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures tumbled in the early New York session, losing nearly 2.75% as traders turned jittery after the release of weak China data. Gold futures were little changed.
The 10-year Treasury note yield rose marginally to 4.096%.
Most major Asian markets ended higher on Monday, led by the Chinese market. The New Zealand and Hong Kong markets pulled back while the Japanese market was closed for a public holiday.
European stocks showed tentativeness and were mostly lower in early trading. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41308384/mark-cuban-clashes-with-bill-ackman-after-billionaire-fund-manager-calls-kamala-harris-startup-tax-d">Mark Cuban Clashes With Bill Ackman After Billionaire Fund Manager Calls Kamala Harris&#8217; Startup Tax Deduction Proposal &#8216;Extremely Misleading:&#8217; &#8216;We Need To Get You Watching Shark Tank&#8217;</a></li>
</ul>
Image Via Shutterstock

Earnings

Futures

Previews

$BTC

MSTR

SIRI

TSLA

Nasdaq, S&P 500 Futures Rise Solidly Ahead Of Q3 Earnings Season, Boeing Drags Dow: This Strategist Sees 'A Lot Of Firepower' Supporting Market After Election

Needham analyst Joshua Reilly reiterates HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and maintains $730 price target.

Reiteration

HUBS

Needham Reiterates Buy on HubSpot, Maintains $730 Price Target

Global Net Lease, Inc. 7.375% CUM PFD E declares $0.4609 dividend

Global Net Lease, Inc. 7.50% CUM PFD D declares $0.4688 dividend

Fed Goes Big

Hurricane Helene: REIT Property Damage Report

Global Net Lease declares $0.275 dividend

The latest update is out from Global Net Lease ( ($GNL) ). Global Net Lease, Inc. has announced a dividend of $0.275 per share for the fourth quart...

Global Net Lease Declares Q4 Dividend Amid Future Uncertainties

Bellevue Capital Partners buys additional 100,000 shares of Global Net Lease

Trick Or Treat, 3 Scary REITs

Global Net Lease closes $569 million of dispositions through Q3

An announcement from Global Net Lease ( ($GNL) ) is now available. Global Net Lease, Inc. has successfully advanced its 2024 strategic disposition ...

Global Net Lease Advances Growth with Strategic Dispositions

APLE

BBRE

FCPT

FREL

GMRE

GOOD

INVH

KBWY

LAMR

PPTY

SCHH

SEVN

SOHO

SRVR

USRT

VRAI

Financing

Press Releases

Global Net Lease Sells Americold Portfolio for $170 Million

Dividends

Global Net Lease, Inc. Announces Common Stock Dividend for the Third Quarter 2024

Global Net Lease Announces $321 Million of Completed Dispositions Through Second Quarter of 2024

Global Net Lease Announces Release Date for Second Quarter 2024 Results

Global Net Lease Reports Second Quarter 2024 Results

Contracts

Global Net Lease Continues Momentum of Strategic Disposition Initiative With Sales of the Plant Shopping Center and Foster Wheeler Office

Global Net Lease, Inc. Announces Preferred Stock Dividends

Global Net Lease, Inc. Announces Common Stock Dividend for the Fourth Quarter 2024

Bellevue Capital Partners Acquires Additional 100,000 Shares of Global Net Lease, Inc. (GNL)

Global Net Lease Completes $569 Million of Dispositions Through Third Quarter of 2024

COLD

American Assets Trust

Armada Hoffler Properties, Inc. Common Stock

Armada Hoffler Properties

Alexander & Baldwin, Inc. Common Stock REIT Holding Company

Alexander & Baldwin

Broadstone Net Lease

CTO Realty Growth

Essential Properties Realty Trust, Inc. Common Stock

Essential Props Realty

Empire State Realty OP, L.P. Series ES Operating Partnership Units Representing Limited Partnership Interests

Empire State Realty OP

Empire State Realty Trust, Inc. Class A Common Stock

Empire State Realty Trust

Generation Income Properties Inc. - Common stock

Generation Income

Gladstone Commercial Corporation - Real Estate Investment Trust

Gladstone Commercial

Medalist Diversified REIT, Inc. - Common Stock

Medalist Diversified REIT

Modiv Industrial, Inc. Class C Common Stock

Modiv Industrial

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Global Net Lease

Global Net Lease (GNL) Forecast

Global Net Lease (NYSE:GNL) Stock, Quote.Headers.trade-ideas